Humacyte

Humacyte Equity Ratio

The Equity Ratio of Humacyte (HUMA) as of Nov 21, 2026 is 2.67 %. In the previous year, Equity Ratio was -38.20 % — a change of -106.99% (higher).

Equity Ratio

2.67 %

YoY

-106.99%

Last updated:

Equity Ratio of Humacyte is 2025 2.67 % . Equity Ratio of Humacyte was 2024 -38.20 % . It decreases by -106.99% higher compared to the previous year.

The Humacyte Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
78.37 USD
Jan 1, 2020
66.24 USD
Jan 1, 2021
42.64 USD
Jan 1, 2022
57.23 USD
Jan 1, 2023
10.56 USD
Jan 1, 2024
-38.20 USD
Jan 1, 2025
2.67 USD
The Humacyte Equity Ratio history
YEAREquity RatioYoY
2.67 %-106.99%
-38.20 %-461.60%
10.56 %-81.54%
57.23 %+34.23%
42.64 %-35.63%
66.24 %-15.47%
78.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Equity Ratio of Humacyte is 2.67 % in 2025.

Equity Ratio of Humacyte changed from -38.20 % to 2.67 %, representing a -106.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Humacyte since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Humacyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Humacyte

All Key Metrics — Humacyte